Business Overview: NeuroOne Medical Technologies Corporation (Nasdaq: NMTC)

---

Executive Summary

NeuroOne Medical Technologies Corporation is a Minnesota-based medical device company developing thin-film electrode technology for diagnosing and treating conditions of the brain and nervous system, including epilepsy, Parkinson's disease, and chronic pain. The company has secured FDA 510(k) clearance for four devices — Evo Cortical, Evo sEEG, the OneRF Brain Ablation System, and the OneRF TN Ablation System — and partners with global orthopedic/neuro device leader Zimmer Biomet, which holds distribution rights for the first three products.

NeuroOne matters as a small but technically differentiated player attempting to displace decades-old electrode technology with thinner, more flexible, higher-resolution devices — a meaningful clinical improvement if it can translate into broader adoption, but one that still depends on scaling commercial revenue well beyond its current small base.

---

1. Core Business Model & How They Work

NeuroOne operates a device-development-and-licensing model, generating revenue both directly and through its Zimmer Biomet distribution partnership:

[ Thin-Film Electrode R&D ] ➡️ [ FDA 510(k) Clearance ] ➡️ [ Direct Sales + Zimmer Biomet Distribution ] ➡️ [ Hospital/Surgeon Adoption ] ➡️ [ Recurring Procedure-Based Device Sales ]

1. Core IP — Thin-Film Electrode Platform: NeuroOne's proprietary thin-film technology is designed to be less invasive and higher-fidelity than legacy electrode products used for brain monitoring and ablation.
2. Partnership-Leveraged Distribution: Rather than building a large sales force from scratch, NeuroOne relies heavily on Zimmer Biomet's existing commercial infrastructure for three of its four cleared products, trading some margin/control for faster market reach.
3. Pipeline Expansion Beyond Neuro: The company is extending its underlying electrode technology into adjacent areas still in development — basivertebral nerve ablation, spinal cord stimulation, and drug delivery — widening its eventual addressable market.

---

2. Product Portfolio

---

3. Competitive Landscape

NeuroOne competes against both specialized niche players and large diversified medical device companies, with the competitive set varying by clinical application:

• Epilepsy diagnostics: Ad-Tech Medical Instrument Corporation, PMT Corporation, Dixi Medical — established legacy electrode suppliers with long-standing hospital relationships.
• Neuro-ablation: Medtronic, Monteris Medical, ClearPoint Neuro — larger, better-capitalized players, several with broader laser-interstitial-thermal-therapy (LITT) platforms.
• Trigeminal neuralgia / pain: Boston Scientific, Avanos Medical.
• Pipeline/development-stage markets (basivertebral nerve ablation, spinal cord stimulation, drug delivery): Boston Scientific, Stryker, Medtronic, Abbott, Globus Medical, Biotronik, ClearPoint Neuro, Sophysa — all substantially larger companies with existing commercial infrastructure in these adjacent markets.

NeuroOne's strategy is to compete on clinical differentiation (thinner, higher-fidelity electrodes) rather than scale, using the Zimmer Biomet partnership to offset its size disadvantage in sales and distribution.

---

4. Strategic Strengths & Risks

Strengths

• Differentiated core technology: Thin-film electrode design offers real clinical advantages (flexibility, resolution, potentially reduced tissue trauma) over legacy electrode designs that have changed relatively little in decades.
• Strategic distribution partnership: The Zimmer Biomet relationship gives a company of NeuroOne's size access to a global commercial and hospital-relationship infrastructure it could not build alone.
• Multiple FDA clearances already secured: Four cleared products (versus a typical early-stage device company with one) de-risks the regulatory story relative to peers.

Risks

• Ongoing capital needs: The company's own risk disclosures note that continued operations depend on raising additional capital (it raised roughly $8.2 million in an April 2025 offering); funding could become more difficult or dilutive in adverse markets.
• Revenue concentration and partner dependence: Because Zimmer Biomet distributes three of four cleared products, NeuroOne's commercial fortunes are partly outside its own direct control.
• Scale disadvantage in adjacent pipeline markets: Spinal cord stimulation and basivertebral ablation pit NeuroOne against giants like Medtronic and Boston Scientific with vastly larger R&D budgets and sales forces.

---

5. Financial Overview

---

6. Summary Conclusion

NeuroOne is a small, technically differentiated medical device company betting that its thin-film electrode platform is a genuine clinical improvement capable of displacing legacy electrode technology across epilepsy diagnostics, neuro-ablation, and eventually pain and spine applications. Its moat today rests almost entirely on patented core technology and its Zimmer Biomet distribution relationship rather than scale or cost position, both of which are modest for a company of its size. The central forward risk is financial as much as competitive: whether the company can fund its pipeline and scale commercial adoption of its newly cleared products before needing further dilutive capital, all while facing much larger, better-resourced competitors in every adjacent market it hopes to enter.